When Should You Start Hormone Therapy? A Charleston Guide to the 10-Year Window

Ashley Harwyn, PA-C · Mount Pleasant & Downtown Charleston

Most women who come to our Mount Pleasant office asking whether hormone therapy is safe are asking the wrong question first. The better question, and the one the research actually answers, is when.

The same treatment started at two different points in a woman's life does not carry the same risk profile, and that single fact explains most of the confusion of the last twenty years. If you are somewhere between 45 and 60 in the Charleston area and wondering whether you have waited too long, this is written for you.

Why did hormone therapy get such a frightening reputation?

Because of one very large trial, and because of who was in it.

The Women's Health Initiative randomized 27,347 postmenopausal women, and their baseline mean age was 63.4 years [4]. For most participants that was well over a decade past menopause. The trial was built to ask whether hormone therapy prevented chronic disease in older women. It was not built to ask whether a 51-year-old with disruptive hot flashes should start treatment, which is the question almost every woman actually has.

When the headlines landed, that distinction did not travel with them.

Here is what the long view showed. Over 18 years of follow-up, all-cause mortality was 27.1 percent in the hormone therapy group versus 27.6 percent in the placebo group [4]. Cardiovascular mortality was flat and total cancer mortality was flat [4]. That is not a finding that hormone therapy extends life. It is a finding that the catastrophe women were led to expect did not appear in the mortality data.

There is one more number in that follow-up worth putting alongside the timing evidence. When the researchers compared the youngest women in the trial, aged 50 to 59, against the oldest, aged 70 to 79, the ratio of hazard ratios for all-cause mortality during the treatment phase was 0.61 [4]. Age at the time of starting was doing something inside a trial that was never designed to ask about it.

What is the timing hypothesis?

The idea that the effects of hormone therapy depend on how soon after menopause it is started.

For years this was an inference drawn from subgroups, which is a weak form of evidence. Then a trial was built specifically to test it. The Early versus Late Intervention Trial with Estradiol enrolled 643 healthy postmenopausal women, sorted them by time since menopause, either less than 6 years or 10 or more years, and randomly assigned oral estradiol or placebo [2]. The primary measure was the rate of thickening of the carotid artery wall, checked every six months for a median of five years.

The part most articles leave out

The same trial found something that deserves equal billing. Estradiol had no significant effect on cardiac CT measures of atherosclerosis in either group [2]. Coronary artery calcium, total stenosis and plaque did not differ from placebo, early starters included.

So the honest summary is narrower than the one usually sold. Starting early was associated with slower thickening of an artery wall, which is a surrogate marker. It was not shown to prevent heart attacks. A surrogate marker is a reasonable thing to weigh when it points the same direction as everything else, and it is not the same as a hard outcome. Anyone telling you hormone therapy prevents heart disease has gone further than this evidence goes.

You would rather hear that from us than discover it later. If the cardiovascular question is the one on your mind, we went deeper into it in heart disease, women and menopause.

Where do the guidelines actually draw the line?

At age 60, or 10 years from your final period, whichever comes first.

The 2022 position statement puts it plainly. For women younger than 60 or within 10 years of menopause onset, with no contraindications, the benefit-risk ratio is favorable for treating bothersome vasomotor symptoms and for preventing bone loss [1]. Vasomotor symptoms is the clinical term for hot flashes and night sweats, and if you are wondering how long those typically last, that has its own answer in how long hot flashes really last.

Past that window, the same statement says the benefit-risk ratio appears less favorable, because of greater absolute risks of coronary heart disease, stroke, venous thromboembolism and dementia [1].

Read those two carefully, because the wording matters. Less favorable is not prohibited. The same statement insists treatment be individualized to maximize benefits and minimize risks, with periodic reevaluation [1]. The window is a starting point for a conversation, not a door that locks on your sixtieth birthday. It also notes that risk differs by type, dose, duration, route of administration, timing of initiation, and whether a progestogen is used [1]. Six variables. Timing is one of them, not the only one.

What changed at the FDA in 2026?

The labels. On February 12, 2026, the FDA announced it had approved labeling changes to six menopausal hormone therapy products, removing risk statements about cardiovascular disease, breast cancer and probable dementia from the boxed warning, the agency's most prominent safety warning [3]. We wrote about the original decision in the FDA removing the black box warning.

The agency's own summary of the evidence names the window directly, stating that randomized studies show women who initiate hormone therapy within 10 years of the onset of menopause, generally before age 60, have a reduction in all-cause mortality and fractures [3].

Two pieces of precision worth having. This is a first batch, not a finished job: 29 drug companies submitted proposed labeling changes and six products have been approved so far [3]. The product you or your pharmacist are looking at may still carry the older language. And the FDA published the scale of the gap: in 2020 about 41 million U.S. women were aged 45 to 64, while only about 2 million women aged 46 to 65 received a hormone therapy prescription [3].

What if you are already past the window?

You are not out of options, and the answer depends on what is bothering you.

For genitourinary symptoms specifically, meaning vaginal dryness, discomfort and urinary changes, the 2022 statement recommends low-dose vaginal estrogen or other local therapies for women without an indication for systemic treatment [1]. That is a local treatment and a different risk conversation entirely, which we covered in is vaginal estrogen safe.

For systemic therapy started later, the guidance is not a refusal. It is that the balance requires more individual scrutiny, because the absolute risks named above are larger in that group [1]. That is a conversation about your cardiovascular history, your bone density, your symptoms, and how much they are costing you.

Does it matter how you take it?

Yes, and this is the part that gets flattened into a single word, hormones, as though every version of it carried the same risk. The 2022 position statement is explicit that the risks of hormone therapy differ depending on type, dose, duration of use, route of administration, timing of initiation, and whether a progestogen is used [1].

Six variables. A conversation that treats hormone therapy as one yes or no decision has collapsed all six into a coin flip. A patch, a gel and a tablet are not interchangeable, and neither are two doses of the same preparation. That is also why a friend's experience, good or bad, tells you less than it feels like it should.

What this article deliberately will not do is tell you which route you should be on. That depends on your history, and the same statement asks that the choice be individualized rather than defaulted [1].

Do you need a progestogen?

It depends on whether you still have a uterus, and it is not an optional extra.

The FDA's 2026 labeling action is precise on this point in a way the headlines were not. Among the four categories covered were systemic estrogen-alone therapy and systemic progestogen-alone therapy for women with a uterus who are using systemic estrogen [3]. The second exists because unopposed estrogen is not appropriate for a woman with a uterus.

What about your bones?

This is the benefit that gets least attention and may matter longest.

Hormone therapy has been shown to prevent bone loss and fracture, and prevention of bone loss sits alongside bothersome vasomotor symptoms in the indication for which the benefit-risk ratio is described as favorable inside the window [1]. The FDA's summary goes further, stating that randomized studies show women who initiate within 10 years of menopause onset have a reduction in all-cause mortality and fractures [3].

Bone loss is quiet. Hot flashes announce themselves and eventually ease for most women, which is covered in how long hot flashes really last. Bone density does not announce anything and does not come back on its own. If symptoms are your only reason for deciding, you are deciding on the loudest variable rather than the most durable one.

How long would you stay on it?

Longer than the five years many women were told, and for reasons that are written down rather than customary.

The guidance is that longer durations of therapy should be for documented indications such as persistent vasomotor symptoms, with shared decision-making and periodic reevaluation [1]. Read that as three conditions rather than a time limit: there is a documented reason, you and your clinician decide together, and the decision gets revisited rather than renewed on autopilot.

Periodic reevaluation is the phrase doing the work. Hormone therapy is not a decision you make once at 52 and never revisit. It is a position you hold and re-examine, because the balance of benefit and risk moves as you do [1].

Getting assessed in Charleston or Mount Pleasant

If the window matters, then so does not spending another year deciding.

Solcara Health sees patients at two Lowcountry locations. The Mount Pleasant office is at 496 Bramson Ct, Ste 120, convenient to Old Village, I'On, Park West and Daniel Island. The downtown practice is at The Longevity Club, 163 Rutledge Ave, Ste 202, in the medical district near MUSC and easy to reach from Harleston Village, Cannonborough and West Ashley.

Ashley Harwyn, PA-C is board certified through the American Academy of Anti-Aging Medicine, and hormone therapy is a core part of this practice rather than something offered alongside everything else.

What a first consultation involves

There is no useful way to answer the timing question from a symptom checklist alone. A first visit is a conversation about your last period and when it happened, your symptom burden and what it is costing you, your personal and family cardiovascular history, bone health, and any contraindications. Laboratory work follows from that conversation rather than preceding it.

Questions women actually ask

Ashley Harwyn, PA-C A4M Board Certified · Founder, Solcara Health Online

Tap a question to ask

About the author

Ashley Harwyn, PA-C

Founder, Solcara Health · Board Certified in Anti-Aging and Functional Medicine (A4M)

Ashley has practiced medicine for more than fifteen years. Her path into it began at home, with a family member born with a congenital heart defect and a childhood spent watching how much the quality of a clinician's attention could change the shape of a life. She has since practiced across a range of settings, including medical mission work in Uganda, before founding Solcara to build the kind of practice she kept wishing existed, one that treats women as whole people and tells them the truth about what the evidence does and does not support.

Full bio →